General Genomics, a biotech and AI company based in Oklahoma City, is redefining athlete brain health with its new neuroimaging augmentation suite - an AI overlay that predicts traumatic brain injury (TBI) risk before symptoms appear. Built on a patented disease susceptibility model and a 630 million-record clinical-genomic dataset, the platform enhances MRI, CT, and PET scans without hardware changes, offering sports medicine teams real-time, individualized risk insights across high school, college, and pro athletes. Already in use by government and commercial clients, this breakthrough tool supports safer return-to-play decisions, longer careers, and a smarter, more preventative approach to neurological care in sports.
General Genomics - Bio Tech/AI in OKC
Written on 06/06/2025